Please assess the completion status of the following clinical trial:

Trial Title: Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~SARS-CoV-2 serology by Akston (a quantitative anti-SARS-Cov-2 SP/RBD-specific IgG ELISA):~* Undetectable or \< 5 μg/mL titer and no known prior SARS-Cov-2 infection~  * Body mass index (BMI) between 19.0 and 30.0 kg/m2, inclusive~ * General good health, without significant medical illness, as determined via physical exam findings, ECG or vital signs~* Note: one retest of vital functions and ECG is allowed within the screening window~  - No clinically significant laboratory abnormalities as determined by the investigator~* Note: one retest of lab tests is allowed within the screening window~  * Informed Consent Form signed voluntarily before any study-related procedure is performed, indicating that the subject understands the purpose and procedures required for the study and is willing to participate in the study~ * Willing to adhere to the prohibitions and restrictions specified in this protocol~ * Non-smoker (including prior smokers having stopped smoking for more than 3 months at time of screening) or non-habitual smoker (habitual smokers are persons who smoke more than 4 cigarettes or other tobacco products on a weekly basis) and agree to not use tobacco products during confinement.~ * Negative alcohol breath test and urine drug screen at screening and upon check-in at the clinical site.~ * Negative hepatitis panel (including hepatitis B surface Ag and anti-hepatitis C virus Abs) and negative human immunodeficiency virus Ab and Ag screens at screening~ * Female subjects should fulfil one of the following criteria:~* At least 1 year post-menopausal (amenorrhea \>12 months and/or follicle stimulating hormone \>30 mIU/mL) at screening;~* Surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation);~* Will use adequate forms of contraceptives from screening to discharge.~  - Female subjects of childbearing potential and male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of birth control from screening to discharge~* Note: medically acceptable methods of contraception that may be used by the subject and/or partner include combined oral contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine device, etonogestrel implant, double barrier, sterilization and vasectomy~  - Female subject has a negative pregnancy test at screening and upon check-in at the clinical site.~* Note: pregnancy testing will consist of a serum pregnancy test at screening and urine pregnancy tests at other (dosing) visits, in all women.~Exclusion Criteria:~A potential subject who meets any of the following criteria will be excluded from participation in this study:~* Pregnant of breastfeeding females~* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, hematologic, rheumatologic, endocrine, autoimmune, or renal disease~* Any laboratory test which is abnormal, and which is deemed by the Investigator(s) to be clinically significant~* Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol~* Current alcohol/illicit drug/nicotine abuse or addiction: history or evidence of current drug use or addiction (positive drug screen for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, or opiates) or excessive use of alcohol at screening and Day -2.~* Presence of any febrile illness (T \> = 38.0°C or lab confirmed viral disease (PCR)) or symptoms suggestive of a viral respiratory infection within 1 weeks prior to vaccination~* Use of corticosteroids (excluding topical preparations for cutaneous or nasal use) or use of immunosuppressive drugs within 30 days before inoculation~* A history of anaphylaxis, history of allergic reaction to vaccine, known allergy to one of the components in AKS-452. Mild allergies without angio-oedema or treatment need can be included if deemed not to be of clinical significance (including but not limited to allergy to animals or mild seasonal hay fever)~* A history of asthma within the past 10 years, or a current diagnosis of asthma or reactive airway disease associated with exercise~* Receipt of a licensed vaccine within 4 weeks prior to viral inoculation~* Received any experimental SARA-CoV-2 vaccine or drug~* Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to vaccination.~* Receipt of another investigational agent within 30 days or 5 times the product half-life (whichever is longest) prior to vaccination~* Shares household with /works with immunocompromised individual(s), adults with significant cardiopulmonary disease, persons with significant asthma, institutionalized elderly or elderly with functional disability~* Deprived of freedom by an administrative or court order or in an emergency setting - Any condition that in the opinion of the principal investigator (PI) would jeopardize the safety or rights of a person participating in the trial or would render the person unable to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- AKS-452 s.c.(A) (Type: EXPERIMENTAL): Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL) single-dose
- AKS-452 s.c. (B) (Type: EXPERIMENTAL): Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL), two-dose
- AKS-452 s.c. (C) (Type: EXPERIMENTAL): Subcutaneous injection of pre-defined dose (45 ug, 205 uL), single-dose
- AKS-452 s.c. (D) (Type: EXPERIMENTAL): Subcutaneous injection of pre-defined dose (45 ug, 250 uL), two-dose
- AKS-452 s.c. (E) (Type: EXPERIMENTAL): Subcutaneous injection of pre-defined dose (90 ug, 500 uL), single-dose
- AKS-452 s.c. (F) (Type: EXPERIMENTAL): Subcutaneous injection of pre-defined dose (90 ug, 500 uL), two-dose
- Phase 2, single-dose injection (Type: EXPERIMENTAL): Subcutaneous injection of selected dose based on phase 1 data, dose (90 ug, 500 uL)
- Phase 2, two-dose injection (Type: EXPERIMENTAL): Subcutaneous injection of selected dose based on phase 1 data, dose (45 ug, 500 uL) twice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete